Table 2.

Treatment details.

	Number	%
Total	179	100
PD1 inhibitors
Nivolumab	72	40
Pembrolizumab	89	50
Othera	18	10
Prior RT
Yes	58	32
No	121	68
Prior cytotoxic
Yes	63	35
No	116	65
Prior SACT
Yes	101	56
No	78	44
Prior ipilimumab
Yes	23	31
No	51	69

Treatment modality received and prior treatment history.

^aOther: Atezolizumab, nivolumab/ipilimumab, durvalumab, cemiplimab, avelumab.